Aslan Pharmaceuticals
Aslan Pharmaceuticals
ASLN
NASDAQ
0.60
USD
0.00%
About
ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin.
It is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The Company is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy for autoimmune disease.
The Company is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 538.4K |
| Three Month Average Volume | 2.2M |
| High Low | |
| Fifty-Two Week High | 19.76 USD |
| Fifty-Two Week Low | 0.475 USD |
| Fifty-Two Week High Date | 28 Jul 2023 |
| Fifty-Two Week Low Date | 17 Jul 2024 |
| Price and Volume | |
| Current Price | 0.6 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -74.99% |
| Thirteen Week Relative Price Change | -83.13% |
| Twenty-Six Week Relative Price Change | -88.78% |
| Fifty-Two Week Relative Price Change | -97.45% |
| Year-to-Date Relative Price Change | -87.45% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | -81.94% |
| Twenty-Six Week Price Change | -87.48% |
| Five Day Price Change | 0.00% |
| Fifty-Two Week Price Change | -96.93% |
| Year-to-Date Price Change | -85.63% |
| Month-to-Date Price Change | -75.00% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 191.9051 USD |
| Book Value Per Share (Most Recent Quarter) | -4.18256 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 191.7711 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -4.19561 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -181.6072 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 49.21308 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1178.754 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -192.396 USD |
| Normalized (Last Fiscal Year) | -1179.206 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1178.754 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -192.396 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1178.754 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -192.396 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1305.381 USD |
| Cash Per Share (Most Recent Quarter) | 193.6237 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1171.145 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -99999.99 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -99999.99 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -5,096 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -375.13% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -6,288.97% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | 100.00% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -369.02% |
| Operating Margin (5 Year) | -6,121.07% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -376.57% |
| Net Profit Margin (5 Year) | -6,306.36% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -38.51% |
| Tangible Book Value (5 Year) | -25.08% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -37.76% |
| Total Debt (5 Year) | 31.20% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 85.59% |
| EPS Change (Trailing Twelve Months) | 81.69% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -2,490,860 |
| Net Debt (Last Fiscal Year) | -19,281,450 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | 0 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 355 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 3 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -38,432,360 |
| Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -13 |
| Net Interest Coverage (Trailing Twelve Months) | -12 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 450 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -66.00% |
| Return on Assets (Trailing Twelve Months) | -77.08% |
| Return on Assets (5 Year) | -77.83% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -156.49% |
| Return on Equity (Trailing Twelve Months) | -426.64% |
| Return on Equity (5 Year) | -192.47% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -81.44% |
| Return on Investment (Trailing Twelve Months) | -110.11% |
| Return on Investment (5 Year) | -96.16% |